Metropolis Q2FY25: Revenue increases 13.4%, PAT 31%

Metropolis Healthcare Limited announced its unaudited financial results for the third quarter of the financial year 2025.

Revenue from operations increased13.4% to Rs 349.8 crore in Q2FY25 compared to Rs 308.5 crore in Q2FY24

Profit after Tax stood at Rs 46.7 crore in Q2FY25, a 31 percent increase from Rs 35.7 crore in Q2FY24.

Reported EBITDA increased 22.2% to Rs 91.5 crore compared to Rs 74.9 crore in Q2FY24.

“We are delighted to share that Q2 FY25 has been a successful quarter, marked by a significant increase in revenue, driven by strong profit after tax (PAT) growth and solid execution from our management team. As we move forward, we will remain focused on advancing our testing capabilities to maintain our differentiated market position and support sustainable long-term growth. Our consistent performance reflects our ability to increase patient volumes while maintaining robust growth trajectories in B2C and B2B segments. With a solid pipeline of future initiatives, including potential mergers and acquisitions, we see a long growth runway ahead in a normalized competitive landscape and are well positioned to capitalize on these opportunities, ensuring long-term value creation for our shareholders,” said Ameera Shah, Executive Chairperson & Whole-time Director, Metropolis Healthcare Limited.

“We have consistently achieved substantial growth, with revenue increasing by 13.4% and EBITDA rising by 22.2% year-on-year. This strong performance has been fuelled by a 21% YoY growth in B2C revenue, along with expansion in Tier 3 cities and an improvement in our average revenue per patient. Key growth areas, including our Specialty and TruHealth segments, have also contributed significantly. As we continue to broaden our footprint through our extensive network and valued partnerships, this strategic approach.”
MB Bureau